Nuwellis decoration

News Release

Nuwellis, Inc. Announces Second Quarter 2022 Financial Results

August 9, 2022

MINNEAPOLIS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the second quarter ended June 30, 2022, which included the following highlights:

  • Generated $2.2 million in total revenue for the second quarter 2022, up 15% sequentially from the first quarter of 2022,
  • Enrolled first patient in REVERSE-HF, a randomized controlled multi-center clinical trial designed to validate clinical outcomes and the economic value of Aquadex therapy, and
  • Decreased operating expenses 14% compared to the second quarter of 2021 to minimize cash utilization while continuing to fund key strategic initiatives.

“I am very happy with our strong sequential performance in the quarter and remain encouraged by our considerable progress in executing our strategy to make the Aquadex System the standard of care for diuretic resistant patients needing fluid balance in the ICU or because of suffering from heart failure,” said Nestor Jaramillo, CEO of Nuwellis. “This includes securing reimbursement for outpatient ultrafiltration therapy, initiating a key pivotal trial, and making strategic enhancements to our product portfolio. We believe these key initiatives position Nuwellis favorably as we look to the back half of 2022 and enter 2023. These results represent the second consecutive quarter where we have reported strong double-digit sequential sales growth, suggesting that the Aquadex System is gaining traction in key academic institutions across the country.”

Second Quarter 2022 Financial Results

Total revenue for the second quarter of 2022 was $2.2 million, an increase of 15% compared to the first quarter of 2022 and a reduction of 12% compared to the prior-year period. Sequential revenue growth in the quarter was driven primarily by strong growth in the Pediatric and Critical Care segments, fueled by higher console sales and increased utilization in certain key accounts.

Gross margin was 48.0% for the second quarter of 2022, compared to 60.2% in the prior-year period. The decline in gross margin compared to the second quarter of 2021 was primarily due to lower fixed overhead absorption, along with a $0.1 million non-cash inventory write-off resulting from the discontinuation of a distribution agreement, partly offset by favorable pricing. Pro forma gross margin would have been 53.1% excluding the one-time inventory charge.

Selling, general and administrative expenses for the second quarter of 2022 were $4.3 million, compared to $5.1 million in the prior-year period. This reduction resulted from continued expense vigilance and certain non-recurring administrative costs in the prior-year period.

Second-quarter research and development expenses were $1.1 million dollars, compared to $1.2 million dollars in the second quarter of 2021, while we continue to advance new product development initiatives.

The net loss for the second quarter of 2022 was $4.3 million, compared to a net loss of $4.7 million in the prior-year period.

Cash and cash equivalents were approximately $15.3 million as of June 30, 2022.

Webcast and Conference Call Information

The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’s performance.

Investors interested in listening to the conference call may do so by following one of the below links:

An audio archive of the webcast will be available following the call on the Investors page at

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, MN, with a wholly owned subsidiary in Ireland.

About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2022 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
    June 30,
  December 31,

ASSETS     (unaudited)      
Current assets            
Cash and cash equivalents   $ 15,345     $ 24,205  
Accounts receivable     1,313       750  
Inventories     3,010       2,843  
Other current assets     252       328  
Total current assets     19,920       28,126  
Property, plant and equipment, net     1,063       1,188  
Operating lease right-of-use asset     994       1,082  
Other assets     21       21  
TOTAL ASSETS   $ 21,998     $ 30,417  
Current liabilities            
Accounts payable   $ 1,550     $ 1,414  
Accrued compensation     1,633       1,664  
Current portion of operating lease liability     186       167  
Current portion of finance lease liability     27       26  
Other current liabilities     63       36  
Total current liabilities     3,459       3,307  
Operating lease liability     860       956  
Finance lease liability     15       28  
Other long-term liability           179  
Total liabilities     4,334       4,470  
Commitments and contingencies            
Stockholders’ equity            
Series A junior participating preferred stock as of June 30, 2022 and December 31, 2021, par value $0.0001 per share; authorized 30,000 shares, none outstanding            
Series F convertible preferred stock as of both June 30, 2022 and December 31, 2021, par value $0.0001 per share; authorized 127 shares, issued and outstanding 127 shares            
Preferred stock as of both June 30, 2022 and December 31, 2021, par value $0.0001 per share; authorized 39,969,873 shares, none outstanding            
Common stock as of June 30, 2022 and December 31, 2021, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 10,537,606 shares     1       1  
Additional paid-in capital     279,350       278,873  
Accumulated other comprehensive income:            
Foreign currency translation adjustment     (12 )     (11 )
Accumulated deficit     (261,675 )     (252,916 )
Total stockholders’ equity     17,664       25,947  

Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
    Three months ended
June 30,
  Six months ended
June 30,
Net sales   $ 2,213     $ 2,508     $ 4,139     $ 4,426  
Cost of goods sold     1,150       997       1,974       1,949  
Gross profit     1,063       1,511       2,165       2,477  
Operating expenses:                                
Selling, general and administrative     4,257       5,063       8,669       10,300  
Research and development     1,107       1,174       2,213       2,121  
Total operating expenses     5,364       6,237       10,882       12,421  
Loss from operations     (4,301 )     (4,726 )     (8,717 )     (9,944 )
Other income (expense), net     17       (2 )     (38 )     (3 )
Loss before income taxes     (4,284 )     (4,728 )     (8,755 )     (9,947 )
Income tax expense     (2 )     (3 )     (4 )     (5 )
Net loss   $ (4,286 )   $ (4,731 )   $ (8,759 )   $ (9,952 )
Basic and diluted loss per share   $ (0.41 )   $ (0.72 )   $ (0.83 )   $ (2.04 )
Weighted average shares outstanding – basic and diluted     10,538       6,532       10,538       4,887  
Other comprehensive loss:                                
Foreign currency translation adjustments   $ 1     $     $ (1 )   $ (3 )
Total comprehensive loss   $ (4,285 )   $ (4,731 )   $ (8,760 )   $ (9,955 )

Condensed Consolidated Statements of Cash Flows
(in thousands)
      Six months ended
June 30,
Operating Activities:                
Net loss   $ (8,759 )   $ (9,952 )
Adjustments to reconcile net loss to cash flows used in operating activities:                
Depreciation and amortization     206       256  
Stock-based compensation expense, net     477       736  
Changes in operating assets and liabilities:                
Accounts receivable     (563 )     (272 )
Inventory     (167 )     122  
Other current assets     76       (176 )
Other assets and liabilities     (152 )     9  
Accounts payable and accrued expenses     117       75  
Net cash used in operating activities     (8,765 )     (9,202 )
Investing Activities:                
Purchases of property and equipment     (81 )     (137 )
Net cash used in investing activities     (81 )     (137 )
Financing Activities:                
Proceeds from public stock offerings, net           18,896  
Proceeds from warrant exercises           1  
Payments on finance lease liability     (13 )     (14 )
Net cash provided (used in) by financing activities     (13 )     18,883  
Effect of exchange rate changes on cash     (1 )     (3 )
Net increase (decrease) in cash and cash equivalents     (8,860 )     9,541  
Cash and cash equivalents - beginning of period     24,205       14,437  
Cash and cash equivalents - end of period   $ 15,345     $ 23,978  
Supplemental cash flow information                
Inventory transferred to property, plant and equipment   $     $ 179  


George Montague, CFA
Chief Financial Officer, Nuwellis, Inc.

Matt Bacso, CFA
Gilmartin Group

Primary Logo

Source: Nuwellis, Inc.